Euro panel backs Rhythm Pharma’s setmelanotide as Orphan Drug

The European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending Orphan Drug designation for Rhythm Pharmaceuticals’ (RYTM -1.2%) setmelanotide for the potential treatment of Bardet-Biedl syndrome, a rare genetic disorder characterized by obesity, visual impairment, learning disabilities and kidney malfunction.

Among the benefits of Orphan Drug status in Europe is a 10-year period of market exclusivity for the indication, if approved.

A final decision from the European Commission usually takes ~60 days.

https://seekingalpha.com/news/3482761-european-advisory-group-backs-rhythm-pharmas-setmelanotide-orphan-drug-rare-inherited